Additionally, HDAC inhibitors were shown to modulate immune responses and ameliorate lupus-like symptoms in experimental models, highlighting the therapeutic potential of targeting histone acetylation in SLE [14,15]. Here, HDAC9 is linked to systemic lupus erythematosus.